To establish whether this situation is preserved in the resistant/metastatic setting, we assessed the frequency of TP53 mutation or deletion across public cohorts in the cBio Cancer Genomics Portal (cBioPortal, http://cbioportal.org) (Fig. 1a). Here, TP53 is linked to cancer.